Sarepta talks eteplirsen, fields questions

• Sarepta Therapeutics (NASDAQ:SRPT) provides updates and color regarding eteplirsen on what seems to have been a generally well-received Q2 conference call.
• Investors should expect 96-week data in October.
• NDA is still expected for H1 2014.
• FDA will look at the totality of the data and could grant full approval (versus accelerated approval) based on robust clinical outcomes.
• Manufacturing scale up is proceeding — the company should be ready for commercial launch by the end of 2014. (webcast)
• Earnings